Recent advances in CAR-T cell engineering
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 C...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Ruihao Huang, Xiaoping Li, Yundi He, Wen Zhu, Lei Gao, Yao Liu, Li Gao, Qin Wen, Jiang F. Zhong, Cheng Zhang and Xi Zhang Tags: Review Source Type: research
More News: Cancer & Oncology | Hematology